Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: A randomized trial

Hepatology Research

Volumn 38, Issue 9, 2008, Pages 954-959

  Enomoto, Masaru ^a   Tamori, Akihiro ^a   Kohmoto, Madoka Toyama ^a   Hayashi, Takehiro ^a   Morikawa, Hiroyasu ^a   Jomura, Hisato ^a   Sakaguchi, Hiroki ^a   Habu, Daiki ^a   Kawada, Norifumi ^a   Shiomi, Susumu ^a   Nishiguchi, Shuhei ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

HBeAg negative chronic hepatitis B; Hepatitis B virus; Lamivudine; YMDD variant

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B CORE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT DURATION;

EID: 48949102508     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00378.x     Document Type: Article

References (37)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.
2. Ganem D, Prince AM. Hepatitis B virus infection -natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
3. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324: 1699-704.
4. Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102-10.
5. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
6. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
7. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
8. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-80.
9. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-34.
10. Kohmoto M, Enomoto M, Yano Y et al. Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: Comparison with three other assays. Hepatol Res 2003; 26: 125-33.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
12. Enomoto M, Nishiguchi S, Seki S, Yamane T, Hino M. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma. Am J Gastroenterol 2004; 99: 1619-20.
13. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
14. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
15. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-13.
16. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-17.
17. Enomoto M, Tamori A, Kohmoto MT et al. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences. J Med Virol 2007; 79: 1664-70.
18. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
19. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
20. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long term follow-up of patients with anti-HBe/ HBV-DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300-6.
21. Usuda S, Okamoto H, Iwanari H et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999; 80: 97-112.
22. Ide T, Kumashiro R, Hino T et al. Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine. Hepatol Res 2001; 21: 76-84.
23. Gerken G, Gomes J, Lampertico P et al. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV-DNA PCR assay. J Virol Methods 1998; 74: 155-65.
24. Stuyver L, Van Geyt C, De Gendt S et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 702-7.
25. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading, and staging. Hepatology 1994; 19: 1513-20.
26. Matsumoto A, Tanaka E, Rokuhara A et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-84.
27. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-55.
28. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
29. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9: 208-12.
30. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003; 46: 329-38.
31. Enomoto M, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab 2006; 52: 43-7.
32. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 432-8.
33. Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: A prospective study. J Hepatol 2003; 39: 614-19.
34. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-91.
35. Suzuki F, Tsubota A, Arase Y et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003; 46: 182-9.
36. Kurashige N, Hiramatsu N, Ohkawa K et al. Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. Hepatol Res 2008; 38: 450-6.
37. Colonno RJ, Rose RE, Pokornowski K et al. Four year assessment of entecavir resistance in nucleoside naïve and lamivudine refractory patients. J Hepatol 2007; 46 (Suppl 1): 294.